Kymera Therapeutics
Stock Forecast, Prediction & Price Target
Kymera Therapeutics (KYMR) stock Price Target by analysts
$56
Potential upside: 31.54%
Kymera Therapeutics price prediction
What is Kymera Therapeutics stock analysts` prediction?
Kymera Therapeutics stock forecast: Based on 3 Wall Street analysts` predicted price targets for Kymera Therapeutics in the last 3 months, the avarage price target is $56, with a high forecast of $NaN. The average price target represents a 31.54% change from the last price of $42.57.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Kymera Therapeutics stock Price Target by analysts
Full breakdown of analysts given Kymera Therapeutics price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Etzer Darout BMO Capital | 0% 0/1 | 9 months ago | $55 29.19% upside | $44.08 | StreetInsider | Previous targets (0) |
Derek Archila Wells Fargo | 0% 0/1 | 9 months ago | $57 33.89% upside | $48.54 | StreetInsider | Previous targets (0) |
Jeff Jones Oppenheimer | 0% 0/2 | 11 months ago | $56 31.54% upside | $49.47 | TheFly | Previous targets (1) |
Andy Chen Wolfe Research | 0% 0/1 | about 1 year ago | $65 52.68% upside | $47.78 | TheFly | Previous targets (0) |
Andrew Fein H.C. Wainwright | 0% 0/2 | about 1 year ago | $60 40.94% upside | $40.31 | StreetInsider | Previous targets (1) |
Andrew Fein H.C. Wainwright | 0% 0/2 | about 1 year ago | $46 8.05% upside | $32.29 | StreetInsider | Previous targets (1) |
Edward Tenthoff Piper Sandler | 0% 0/1 | over 1 year ago | $56 31.54% upside | $34.84 | StreetInsider | Previous targets (0) |
Jeff Jones Oppenheimer | 0% 0/2 | over 1 year ago | $52 22.15% upside | $36.3 | StreetInsider | Previous targets (1) |
Unknown Wells Fargo | N/A | over 2 years ago | $42 -1.33% downside | $24.71 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | over 2 years ago | $41 -3.68% downside | $27.05 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | over 2 years ago | $52 22.15% upside | $28.26 | Benzinga | N/A |
Unknown Leerink Partners | N/A | over 2 years ago | $31 -27.17% downside | $29.62 | Benzinga | N/A |
Richard Law Credit Suisse | 100% 1/1 | almost 3 years ago | $32 -24.82% downside | $29.11 | TheFly | Previous targets (0) |
Michael Turits Morgan Stanley | 0% 0/1 | almost 3 years ago | $45.2 6.17% upside | $29.11 | Benzinga | Previous targets (0) |
Unknown Morgan Stanley | N/A | about 3 years ago | $37 -13.08% downside | $31.81 | Benzinga | N/A |
Unknown Credit Suisse | N/A | about 3 years ago | $61 43.29% upside | $32.83 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | over 3 years ago | $35 -17.78% downside | $21 | Benzinga | N/A |
Unknown Credit Suisse | N/A | over 3 years ago | $60 40.94% upside | $21.27 | Benzinga | N/A |
Eliana Merle UBS | 0% 0/1 | over 4 years ago | $80 87.92% upside | $43.2 | TheFly | Previous targets (0) |
Kymera Therapeutics Financial Estimates
Kymera Therapeutics Revenue Estimates
Kymera Therapeutics EBITDA Estimates
Kymera Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $72.83M N/A | $46.82M -35.70% | $78.59M 67.83% | Avg: $70.77M Low: $16.19M High: $145.17M avg. -9.94% | Avg: $77.17M Low: $19.42M High: $160.31M avg. 9.03% | Avg: $143.42M Low: $36.10M High: $297.93M avg. 85.84% | Avg: $263.61M Low: $66.36M High: $547.61M avg. 83.80% |
Net Income
% change YoY
| $-97.99M N/A | $-151.83M -54.93% | $-146.96M 3.20% | Avg: $-239.51M Low: $-247.46M High: $-116.73M avg. -62.97% | Avg: $-261.59M Low: $-295.91M High: $-97.47M avg. -9.21% | Avg: $-171.14M Low: $-410.82M High: $-4.66M avg. 34.57% | Avg: $-137.48M Low: $-330.02M High: $-3.74M avg. 19.66% |
EBITDA
% change YoY
| $-100.04M N/A | $-154.63M -54.56% | $-143.20M 7.39% | Avg: $-70.77M Low: $-145.17M High: $-16.19M avg. 50.57% | Avg: $-77.17M Low: $-160.31M High: $-19.42M avg. -9.03% | Avg: $-143.42M Low: $-297.93M High: $-36.10M avg. -85.84% | Avg: $-263.61M Low: $-547.61M High: $-66.36M avg. -83.80% |
EPS
% change YoY
| -$2.04 N/A | -$2.82 -38.23% | -$2.52 10.63% | Avg: -$3.27 Low: -$4.24 High: -$2 avg. -29.62% | Avg: -$3.39 Low: -$5.07 High: -$1.67 avg. -3.69% | Avg: -$2.93 Low: -$7.04 High: -$0.08 avg. 13.43% | Avg: -$2.36 Low: -$5.65 High: -$0.06 avg. 19.66% |
Operating Expenses
% change YoY
| $173.36M N/A | $208.08M 20.02% | $244.12M 17.32% | Avg: $76.31M Low: $17.46M High: $156.54M avg. -68.73% | Avg: $83.21M Low: $20.94M High: $172.86M avg. 9.03% | Avg: $154.65M Low: $38.93M High: $321.25M avg. 85.84% | Avg: $284.24M Low: $71.55M High: $590.47M avg. 83.80% |
FAQ
What is Kymera Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -4.48% in 2025-2028.
We have gathered data from 15 analysts. Their low estimate is -247.46M, average is -239.51M and high is -116.73M.
What is Kymera Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 42.18% in 2025-2028.
We have gathered data from 15 analysts. Their low revenue estimate is $16.19M, average is $70.77M and high is $145.17M.
What is Kymera Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -0.05% in 2025-2028.
We have gathered data from 15 analysts. Their low earnings per share estimate is -$4.24, average is -$3.27 and high is $-2.
What is the best performing analyst?
In the last twelve months 3 analysts have been covering Kymera Therapeutics stock. The most successful analyst is Etzer Darout.